Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 235.92M P/E - EPS this Y 18.90% Ern Qtrly Grth -
Income -97.33M Forward P/E -1.90 EPS next Y -24.80% 50D Avg Chg 13.00%
Sales 2.81M PEG -0.35 EPS past 5Y - 200D Avg Chg -34.00%
Dividend N/A Price/Book 0.80 EPS next 5Y 16.40% 52W High Chg -75.00%
Recommedations 1.90 Quick Ratio 17.44 Shares Outstanding 62.15M 52W Low Chg 70.00%
Insider Own 1.39% ROA -28.56% Shares Float 38.53M Beta 2.35
Inst Own 99.76% ROE -44.84% Shares Shorted/Prior 3M/2.26M Price 3.82
Gross Margin - Profit Margin - Avg. Volume 720,272 Target Price 15.78
Oper. Margin -3,213.78% Earnings Date Aug 1 Volume 367,973 Change 2.96%
About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics, Inc. News
05/26/24 Goldman Sachs Predicts up to 108% Rally for These 2 ‘Strong Buy’ Stocks
05/17/24 The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
05/16/24 Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
05/15/24 Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
05/14/24 Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
05/14/24 Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
05/13/24 Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
05/13/24 Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
05/13/24 Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
05/13/24 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
05/13/24 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
05/09/24 Fulcrum Therapeutics to Participate in Upcoming May Conferences
05/08/24 Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
05/06/24 Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
03:05 PM Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
03/22/24 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/18/24 Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
03/07/24 CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock
03/05/24 Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
02:27 PM Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations
FULC Chatroom

User Image Doorkey Posted - 10 hours ago

$FULC It just gets better. https://finance.yahoo.com/news/goldman-sachs-predicts-108-rally-130213207.html

User Image tradingtwenty Posted - 1 day ago

Top 5 trending stocks in the past 24 hours (based on 5 minute intervals): $PATH 207 🔥 $FULC 192 $COST 145 $LUCY 132 $MSI 129 Link: https://tradingtwenty.com/dashboard/trending/past

User Image TipRanks Posted - 2 days ago

Goldman Sachs Predicts up to 108% Rally for These 2 ‘Strong Buy’ Stocks https://www.tipranks.com/news/article/goldman-sachs-predicts-up-to-108-rally-for-these-2-strong-buy-stocks $FULC $MRX

User Image Doorkey Posted - 3 days ago

$FULC Oh hell yeah! Added more.

User Image Doorkey Posted - 4 days ago

$FULC Can't wait for when this recovers. Big money in this. https://whalewisdom.com/stock/fulc

User Image Doorkey Posted - 4 days ago

$FULC Added more for swing.

User Image Doorkey Posted - 5 days ago

$FULC Thank you dip Gods.

User Image Doorkey Posted - 5 days ago

$FULC Wanna swing at $9

User Image BestNwest Posted - 1 week ago

$FULC

User Image erevnon Posted - 1 week ago

Cantor Fitzgerald initiates coverage on Fulcrum Therapeutics $FULC at Overweight and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image RiskyBuzz Posted - 1 week ago

$FULC If this is accurate then I will see a juicy profit..

User Image Doorkey Posted - 1 week ago

$FULC Cantor with overweight $23 PT We'll see sum nice movement this week.

User Image RobInTheHat Posted - 1 week ago

$FULC

User Image RobInTheHat Posted - 1 week ago

$FULC https://www.tipranks.com/stocks/fulc/forecast#

User Image vmsrena Posted - 1 week ago

$FULC In for 25k shares @ 7.43 will add on dip tomorrow if that happens.

User Image TimingTimingTiming Posted - 1 week ago

$FULC Well Fulc!

User Image RobInTheHat Posted - 1 week ago

$FULC in for 50 @7.96. We’ll see…

User Image PKlee Posted - 1 week ago

$FULC Assuming Ph3 fshd drug goes well, does anyone here also think that FULC would be a good acquisition target (Sanofi)?

User Image RiskyBuzz Posted - 1 week ago

$FULC I’m in in this one.... Big explosion coming soon

User Image Doorkey Posted - 1 week ago

$FULC LFG!

User Image SalocinCo Posted - 1 week ago

$FULC 🎢〽️🎢〽️🎢🎢

User Image erevnon Posted - 2 weeks ago

Goldman Sachs upgrades Fulcrum Therapeutics $FULC from Neutral to Buy and raises the price target from $6 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image anachartanalyst Posted - 2 weeks ago

https://anachart.com/market-update/may-14th-2024/ $FULC $AGYS $DCBO

User Image KimAntony Posted - 2 weeks ago

$FULC upgraded to buy this morning by Golman Sachs with the PT increased from $7.47 to $15.00 - https://www.streetinsider.com/rating_history.php?q=fulc

User Image erevnon Posted - 2 weeks ago

Oppenheimer maintains Fulcrum Therapeutics $FULC at Outperform and lowers the price target from $16 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Thestocktraderhubzee Posted - 2 weeks ago

WATCHLIST MAY 14 2024 $QBTS Needham Reiterates Buy on D-Wave Quantum, Maintains $2.5 Price Target $RBLX Roth MKM Downgrades Roblox to Neutral, Lowers Price Target to $35 $TENB Needham Reiterates Buy on Tenable Holdings, Maintains $62 Price Target $FULC Oppenheimer Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $14 $WBD Barrington Research Maintains Outperform on Warner Bros. Discovery, Lowers Price Target to $15

User Image kellyCriterion101 Posted - 2 weeks ago

$FULC unfortunately this looks priced for failure (the p2 may paper online tells you this too). But if it works, $50 stock. I’m long btw. Also the patients on this have signed a strict nda

User Image BestNwest Posted - 2 weeks ago

$FULC

User Image RonIsWrong Posted - 2 weeks ago

$FULC and more today. another 3500 of the $10/$22s call spread- I assume that's added to the OI - will verify tomorrow. Since I posted back on March 25th, the open interest increase by more than 6000 contracts. + GS price upgrade today + Stifel price upgrade today

User Image Chingying Posted - 2 weeks ago

$FULC Topline data for Phase 3 for FSHD: Q4 2024, in 5-7 months

Analyst Ratings
Cantor Fitzgerald Overweight May 20, 24
Goldman Sachs Buy May 14, 24
HC Wainwright & Co. Buy May 14, 24
Oppenheimer Outperform May 14, 24
Goldman Sachs Buy May 13, 24
RBC Capital Outperform Mar 13, 24
HC Wainwright & Co. Buy Feb 28, 24
Piper Sandler Overweight Feb 28, 24
Goldman Sachs Neutral Jan 26, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Jan 20 Buy 13.00 1,923,076 24,999,988 11,609,704 01/24/23
Gould Robert J Interim President &.. Interim President & CEO Jan 13 Sell 15.00 6,766 101,490 499,864 01/13/23
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Dec 27 Buy 5.9941 4,089 24,510 9,505,925 12/29/22
Gould Robert J Director Director Jun 07 Option 7.84 71,435 560,050 578,065 06/08/22
Gould Robert J Director Director Jun 07 Sell 8.09 71,435 577,909 506,630 06/08/22
Gould Robert J Director Director Jun 02 Option 7.84 66,622 522,316 531,012 06/06/22
Gould Robert J Director Director Jun 02 Sell 7.99 66,622 532,310 506,630 06/06/22
Gould Robert J Director Director Apr 07 Option 7.84 5,631 44,147 512,261 04/11/22
Gould Robert J Director Director Apr 07 Sell 24.02 5,631 135,257 506,630 04/11/22
Gould Robert J Director Director Apr 01 Option 7.84 94,251 738,928 559,182 04/05/22
Gould Robert J Director Director Apr 01 Sell 24.1 94,251 2,271,449 506,630 04/05/22